USANA Health Sciences (NYSE:USNA) issued an update on its third quarter 2021 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.
Shares of NYSE USNA traded up $0.90 during trading hours on Friday, hitting $89.93. The stock had a trading volume of 83,752 shares, compared to its average volume of 89,432. The company has a market capitalization of $1.80 billion, a P/E ratio of 13.56 and a beta of 0.85. The firm’s 50-day moving average price is $95.63 and its two-hundred day moving average price is $98.53. USANA Health Sciences has a 52 week low of $72.03 and a 52 week high of $107.85.
USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, July 27th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The firm had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $340.20 million. USANA Health Sciences had a return on equity of 33.65% and a net margin of 11.09%. Equities research analysts anticipate that USANA Health Sciences will post 6.31 earnings per share for the current fiscal year.
In other USANA Health Sciences news, Director John Turman Fleming sold 300 shares of the stock in a transaction on Monday, August 30th. The stock was sold at an average price of $97.26, for a total transaction of $29,178.00. Following the completion of the transaction, the director now directly owns 851 shares in the company, valued at $82,768.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frederic J. Winssinger sold 926 shares of the stock in a transaction on Thursday, July 29th. The stock was sold at an average price of $99.08, for a total value of $91,748.08. Following the transaction, the director now owns 2,516 shares of the company’s stock, valued at $249,285.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,435 shares of company stock valued at $331,837. Corporate insiders own 0.21% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.
Featured Article: Why are analyst ratings important in trading stocks?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.